Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors

Abstract excerpt

In the past decade, recombinant vectors based on a non-pathogenic parvovirus, the adeno-associated virus (AAV), have taken center stage as a gene delivery vehicle for the potential gene therapy for a number of human diseases. To date, the safety of AAV vectors in 176 phase I, II, and III clinical trials and their efficacy in at least eight human diseases are now firmly documented. Despite these remarkable...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to RNA Interference and Gene Delivery
• Share to Viral Infections and Immunology Research
• Share to Virus-based gene therapy research